Caribou Biosciences’ (CRBU) Buy Rating Reaffirmed at HC Wainwright

Caribou Biosciences (NASDAQ:CRBU)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 361.54% from the stock’s current price.

A number of other research firms also recently issued reports on CRBU. Truist Financial raised shares of Caribou Biosciences to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Caribou Biosciences has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Caribou Biosciences Trading Up 0.5%

CRBU stock opened at $1.95 on Tuesday. The company has a market cap of $188.45 million, a PE ratio of -1.23 and a beta of 2.46. The stock has a 50-day moving average price of $1.77 and a two-hundred day moving average price of $1.91. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. The company had revenue of $3.94 million during the quarter, compared to analyst estimates of $1.96 million. Caribou Biosciences had a negative return on equity of 78.40% and a negative net margin of 1,327.40%. Equities analysts forecast that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CRBU. AQR Capital Management LLC boosted its position in shares of Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after buying an additional 463,391 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Caribou Biosciences in the 1st quarter worth about $61,000. Creative Planning bought a new stake in shares of Caribou Biosciences in the 2nd quarter worth about $25,000. XTX Topco Ltd bought a new position in Caribou Biosciences during the 2nd quarter worth approximately $133,000. Finally, RBF Capital LLC bought a new position in Caribou Biosciences during the 2nd quarter worth approximately $101,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.